Trial Profile
A phase I/II consortium study to evaluate safety and activity of temsirolimus and bevacizumab in patients advanced renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 28 Oct 2015 New trial record